Day: April 22, 2020

Co-primary endpoints met with 75.2% response rate for dysmenorrhea (menstrual pain) (p < 0.0001) and 66.0% response rate for non-menstrual pelvic pain (p < 0.0001)Women receiving relugolix combination therapy, on average, had a 75.1% reduction on the Numerical Rating Scale for dysmenorrhea from 7.2 (severe pain) to 1.7 (mild pain)Achieved six key secondary endpoints, including improvement in impact of pain on daily activities and a greater proportion of women not using opioids, with a generally well-tolerated safety profile including minimal bone mineral density lossDemonstrated 100% ovulation inhibition and 100% return of ovulation or menses upon discontinuation of treatment in a separate study  Conference call and webcast to be held today at 8:30 a.m. EDT / 5:30 a.m. PDTBASEL, Switzerland, April 22, 2020 (GLOBE NEWSWIRE) — Myovant...

RAUTE OYJ SIJOITTAJAUUTINEN 22.4.2020 KLO 14.30RAUTEN OSAVUOSIKATSAUKSEN JULKISTAMINEN JA ESITTELYRaute Oyj julkistaa 1.1.-31.3.2020 (3 kk) osavuosikatsauksen keskiviikkona 29.4.2020 noin klo 9.00. Analyytikoilla, sijoittajilla ja tiedotusvälineillä on mahdollisuus seurata osavuosikatsauksen esittelyä verkossa samana päivänä 29.4.2020 alkaen klo 14.00 tästä linkistä. Osavuosikatsauksen esittelevät toimitusjohtaja Tapani Kiiski ja talousjohtaja Tarja Järvinen.Analyytikot, sijoittajat ja tiedotusvälineet voivat lähettää ennakkoon osavuosikatsaukseen liittyviä kysymyksiä sähköpostiosoitteeseen ir@raute.com 29.4.2020 klo 14.30 saakka, jonka jälkeen toimitusjohtaja Tapani Kiiski ja talousjohtaja Tarja Järvinen vastaavat lähetettyihin kysymyksiin suorassa osavuosikatsauksen esittelyssä noin klo 15.00 saakka. Toimitusjohtaja Tapani Kiiski on myös...

RAUTE CORPORATION INVESTOR NEWS 22 April 2020 at 2:30 p.m.PUBLICATION AND PRESENTATION OF RAUTE CORPORATION’S INTERIM REPORTRaute Corporation will publish its interim report for January 1 – March 31, 2020 (3 months) on Wednesday, April 29, 2020 at about 9 a.m. Finnish time. Analysts, investors and media representatives may follow a live stream presentation of the interim report (in Finnish) through this link starting at 2:00 p.m. on April 29, 2020.  The interim report will be presented by President and CEO Tapani Kiiski and CFO Tarja Järvinen.Analysts, investors and media representatives can send questions concerning the interim report by email to ir@raute.com on April 29, 2020 up to 2:30 p.m., after which President and CEO Tapani Kiiski and CFO Tarja Järvinen will answer these questions in the online interim report presentation...

Please find below a press release from Aedifica (a public regulated real estate company under Belgian law, listed on Euronext Brussels and Euronext Amsterdam), regarding the issuance of up to 2,460,115 New Shares via an accelerated bookbuilding with international institutional investors.AttachmentsPress release ENCommuniqué de presse FRPersbericht NL

NEWTOWN, Pa., April 22, 2020 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the appointment of Jeffrey S. Mathiesen, CPA, to its Board of Directors, effective as of June 9, 2020. Upon his appointment, Mr. Mathiesen will serve as Chair of the Company’s Audit Committee.“Jeff joins our Board of Directors with more than 25 years of experience as Chief Financial Officer of numerous growth-oriented, technology-based companies, including significant experience in the healthcare sector,” said Philippe Deschamps, Chief Executive Officer of Helius Medical Technologies and Chairman of the Board of Directors. “I am very honored to welcome such an accomplished financial expert to our Board and look forward to leveraging...

ALPHARETTA, Ga., April 22, 2020 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Nancy J. Hutson, Ph.D. has been appointed to the Company’s Board of Directors, effective April 21, 2020.“The addition of Nancy Hutson to our Board of Directors comes at a key time as we are expanding our research and development pipeline and preparing to initiate a clinical program targeting the treatment of wet age-related macular degeneration with CLS-AX,” said William Humphries, Chairman of the Clearside Board of Directors. “Nancy brings a deep understanding of the business coupled with an in-depth knowledge of research, drug development and dynamic...

RESEARCH TRIANGLE PARK, N.C., April 22, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2020 financial results on Wednesday, May 6, 2020.BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 4679821. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 4679821.About...

Reported net revenue of $1.97 billion, a decrease of 1.6% from a year ago, with organic net revenue growth of 0.3%In seasonally small quarter, net income was $4.7 million compared with a loss of $8.0 million a year ago, with EBITA of $97.2 million and EBITA margin of 4.9%First quarter diluted EPS was $0.01 and $0.11 as adjustedManagement highlights strategic and operating strengths, exceptional talent base, deep financial resources, and flexible cost model, amid macroeconomic and marketing uncertainty due to COVID-19 pandemicNew York, April 22, 2020 (GLOBE NEWSWIRE) —SummaryRevenueFirst quarter 2020 net revenue decreased 1.6% to $1.97 billion, compared to $2.00 billion in the first quarter of 2019. During the quarter, the organic net revenue increase was 0.3%, while the effect of foreign currency translation was negative 1.0%, and...

TORONTO, April 22, 2020 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) is pleased to report that it has filed an updated technical report in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects for the Valentine Gold Project in central Newfoundland, available on SEDAR (www.sedar.com).The technical report is entitled “N.I. 43-101 Technical Report & Pre-Feasibility Study on the Valentine Gold Project, Newfoundland and Labrador, Canada” and has been prepared by Ausenco Engineering Canada Inc. with an effective date of April 18, 2020.The Valentine Gold Project Pre-Feasibility Study (“PFS”) supports an open pit mining operation with low initial capital cost and high rate of return over a 12-year mine life (see Marathon news release dated April 6, 2020). Highlights...